Clinicodemographic profile, intensive care unit utilization and mortality rate among COVID-19 patients admitted during the second wave in Bangladesh

Sultana Parvin 1,∗, Md. Samiul Islam 2, Touhidul Karim Majumdar 1, Faruque Ahmed 1

1 Department of Medical Gastroenterology, Sheikh Russel National Gastroliver Institute & Hospital, Mohakhali, Dhaka 1212, Bangladesh
2 National Institute of Traumatology & orthopedic rehabilitation, (NITOR) Dhaka-1207, Bangladesh

A R T I C L E   I N F O

Keywords:
COVID-19 clinicodemographic profile second wave ICU utilization rate mortality rate

A B S T R A C T

Introduction: The second wave of COVID-19 arrived in Bangladesh in March 2021. This pilot research from a tertiary care COVID-dedicated hospital observed the clinicodemographic profile, intensive care unit (ICU) utilization, and mortality rate among COVID-19 patients admitted during the second wave.

Methods: Reverse transcription-polymerase chain reaction or chest high-resolution computed tomography confirmed 972 COVID-19 cases included in this cross-sectional study from 24 March to 23 June 2021, recruited using convenience sampling. Data regarding clinicodemographic profile, ICU utilization and mortality rate were analyzed.

Results: The mean study cohort age was 54.47±12.73 years, with most patients (48.3%) aged 41–60; 64.1% were men. Fever (77.9%) and cough (75.9%) were the most common symptoms, and hypertension (43.6%) and diabetes (42.15%) the most common comorbidities. Nearly half of patients had total lung involvement of 26%–50%, and 23.8% required ICU. Overall mortality was 16.5%, whereas the mortality rate among ICU admitted patients was 56.1%. The most important predictors of mortality were older age, chronic renal illness, the proportion of lung involvement and ICU requirement.

Conclusions: We found higher mortality and ICU utilization rate and greater total lung involvement during the second wave. The mortality rate among the elderly and ICU patients was also higher than earlier.

Introduction

The SARS-CoV-2 pandemic began in Wuhan, China, in December 2019 and swiftly spread around the world, culminating in wave after wave of outbreaks (Ridruejo and Soza, 2020, Taboada et al., 2021). The World Health Organization (WHO) designated the new illness as COVID-19 (Lippi et al., 2020). On 30 January 2020, the WHO proclaimed COVID-19 a Public Health Emergency of International Concern, and on 11 April 2020, it was declared a pandemic (Cucinotta and Vanelli, 2020). Based on information from the affected nations, the WHO has reported 185 291 530 laboratory-confirmed cases of COVID-19 with 4 010 834 deaths as of 9 July 2021 (WHO, 2021).

Although more than half of COVID-19 cases are asymptomatic, others develop symptoms ranging from flu-like episodes, including fever, cough and myalgia, to pneumonia. Age, sex and comorbid illness are associated with the severity of the disease that causes multiorgan involvement and death (Chan et al., 2020, Soriano et al., 2021). The majority of COVID-19 disease (~80%) presents in a mild form and may be managed without hospitalization. Admission is required in 15%–20% of patients, and critical care is required in 3%–5% of cases, with reported fatality rates ranging from 50% to 97% in those requiring ventilatory support (Auld et al., 2020, Wu and McGoonan, 2020).

Since the first case was documented at the beginning of March 2020, 568 706 people in Bangladesh have tested positive for COVID-19, and 8668 people have died, resulting in a fatality rate of 1.52% to 20 March 2021. Overall daily case detection began to drop in early December 2020, and in early January 2021, the detection fell below 1000 per day. However, the number of cases detected and the rate of case referral to hospitals increased again on 16 March 2021, indicating the commencement of the second wave of the pandemic. According to recent studies from other nations, the second wave has much higher infection rates,
intensive care unit (ICU) utilization and mortality (Graichen, 2021, Jain et al., 2021).

There is currently a paucity of data on the second wave in Bangladesh. To the authors’ knowledge, our study is the first to investigate the clinicodemographic profile, ICU utilization and mortality rate among the COVID-19 admitted cases during the second wave. The research will also provide information on the symptomatology and comorbidity associated with the current wave.

Methods

This cross-sectional study was conducted in a tertiary care COVID-19 specialist hospital during the peak of the second wave (from 24 March to 23 June 2021). The 250-bed hospital is located in the Bangladesh capital and serves 10.9 million people in the city’s northern reaches. Using convenience sampling, 972 confirmed COVID-19 cases were included on the basis of diagnostic reverse transcription-polymerase chain reaction (RT-PCR) and/or positive chest high-resolution computed tomography (HRCT). Patients under the age of 18 years were excluded. The study was approved by the institutional review board of the COVID-19 dedicated hospital, who waived the requirement for informed consent in the face of a pandemic scenario.

A pro forma data sheet for demographics, symptoms, comorbidity, HRCT findings, ICU utilization, patient vital status and patient outcome was used to collect data. If necessary, a chest HRCT was performed, and all HRCTs were reported by the same specialist radiologist. Each patient’s HRCT severity score was calculated based on lung involvement by calculating the percentage of each lobar involvement separately and allocating a number between 1 and 5, with a score of 1 signifying 5% involvement, score 2:5%–25% involvement, score 3:26%–50% involvement, score 4:51%–75% involvement and Score 5: >75% involvement. The patient’s ultimate score was computed out of 25 by adding the individual lobar scores. The total lung involvement was then calculated by multiplying the ultimate score by 4. Finally, the extent of total lung involvement was categorized as follows: Minimal involvement: 1%–25% of total lung volume, mild involvement: 26%–50%, moderate involvement: 51%–75% and >75% lung involvement was considered severe (Al-Mosawe et al., 2021, Francone et al., 2020).

Statistical Package for the Social Sciences software (v.23; IBM Corporation, Armonk, New York) was used for the statistical analysis. Numbers and percentages were used to represent categorical data. The mean and standard deviation were used to present numerical data. The Chi-square test was used to examine qualitative factors, while an unpaired t-test was used to assess quantitative data. The cutoff for statistical significance was determined at P<0.05.

Results

During the research period, 983 patients were admitted to the tertiary care COVID-19 specialized hospital. A total of 972 individuals were included in the research after excluding 11 patients (3 patients were <18 years old; 8 patients had symptoms but were negative for COVID-19 on both chest HRCT and RT-PCR). The average age of study participants was 54.47±12.73 years; 64.1% were men. The majority of the study population (48.3%) were aged 41–60 years. Most patients had one or more of the following comorbid conditions: hypertension (HTN) (43.6%), diabetes mellitus (DM) (42.1%), bronchial asthma (BA) (9.7%), ischemic heart disease (IHD) (7.8%), chronic kidney disease (CKD) (4.7%) and cancer (2.2%). Participants with no comorbidities were 34.1% of participants, whereas 33.1% had at least one. Fever and cough were the most prevalent patient complaints, accounting for 77.9% and 75.9% of all cases, respectively. Shortness of breath affected 38.6% of patients, diarrhea 19.1% of patients, and body aches 15.2% of patients. Only ∼12% of the patients had anosmia, lethargy or chest discomfort (Table 1). Chest HRCT was performed in more than 65.5% of the study population, 7.2% of whom were severe cases. Minimal to mild changes were found in 68% of cases. Out of 972 patients, 232 (23.8%) needed critical care support (Table 2). The overall mortality rate was 16.5% among all study participants (Figure 1(a)), while the mortality rate among patients admitted to ICU was 56.1% (Figure 1(b)). A comparison between patients who died and those who were discharged revealed that older age, male gender, presence of HTN and DM, along with CKD, carcinoma and inflammatory bowel disease, were significantly associated with mortality. Those who died had higher lung involvement percentages and ICU utilization rates (Table 3). There were no significant differences in gender or associated comorbidities between patients admitted to ICU and those not admitted to ICU. On the other hand, compared to non-ICU patients, ICU patients were significantly older, with a higher mortality rate and a greater percentage of lung involvement in chest HRCT (Table 4).

### Table 1

Clinicodemographic characteristics of the patients (n = 972)

| Characteristics                  | Group     | Mean±SD | n   |
|----------------------------------|-----------|---------|-----|
| Age (in years)                   | <20       | 12±1.2  | 259 |
|                                 | 21-40     | 54.47±12.73 | 188 |
|                                 | 41-60     | 470±48.3 | 302 |
|                                 | >60       | 302±31.0 | 302 |
| Sex                              | Male      | 624±64.1 | 624 |
|                                 | Female    | 348±35.8 | 348 |
| Number of comorbidities          | None      | 332±34.1 | 332 |
|                                 | 1         | 322±33.1 | 322 |
|                                 | 2         | 228±23.4 | 228 |
|                                 | 3 or above| 90±9.2  | 90  |
| Specific comorbidity             | HTN       | 42±43.6  | 42  |
|                                 | DM        | 41±42.1  | 41  |
|                                 | BA        | 95±27    | 95  |
|                                 | IHD       | 76±7.8   | 76  |
|                                 | CKD       | 46±4.7   | 46  |
|                                 | Carcinoma | 22±2.2   | 22  |
|                                 | COPD      | 14±1.4   | 14  |
|                                 | Liver Disease | 14±1.4 | 14 |
|                                 | IBD       | 11±1.1   | 11  |
| Predominant symptoms            | Fever     | 758±77.9 | 758 |
|                                 | Cough     | 738±75.9 | 738 |
|                                 | SOB       | 376±38.6 | 376 |
|                                 | Diarrhea  | 186±19.1 | 186 |
|                                 | Body Ache | 148±15.2 | 148 |
|                                 | Anosmia   | 57±5.8   | 57  |
|                                 | Lethargy  | 37±3.8   | 37  |
|                                 | Chest pain| 23±2.3   | 23  |

Values are presented as frequency, percentage, and mean±SD; percentage in the parentheses.

Hypertension (HTN), diabetes mellitus (DM), bronchial asthma (BA), ischemic heart disease (IHD), chronic kidney disease (CKD), inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD)

### Table 2

CT involvement of lung and severity grade with ICU requirement

| CT involvement of lung | Number of Patients n (%) | Mean±SD |
|------------------------|--------------------------|---------|
| Yes                    | 63/65.5                  |         |
| No                     | 335/34.4                 |         |
| Grade of CT involvement | Extent of involvement (%) |       |
| Minimal                | 1-25                     | 312±19.6|         |
| Mild                   | 26-50                    | 310(48.6)| 44.8±18.8|
| Moderate               | 51-75                    | 156(24.4)|         |
| Severe                 | >75                      | 46(7.2) |         |
| ICU Required           | Yes                      | 232(23.8)|         |
|                        | No                       | 740(76.1)|         |

Values are presented as frequency, percentage, and mean±SD; percentage in the parentheses.

Computed tomography (CT), intensive care unit (ICU)
Table 3
Comparison of clinico-demographic profile between discharged and not survived patients (n=972)

| Outcome                      | Not survived (n = 161) | Discharged (n = 161) | P value |
|------------------------------|------------------------|----------------------|---------|
| Age (Mean±SD)                | 61.39±11.64            | 50.44±14.17          | 0.001   |
| Sex                          |                        |                      |         |
| Male                         | 127                    | 62.1                 | 0.001*  |
| Female                       | 34                     | 314                  |         |
| Comorbidity                  |                        |                      |         |
| DM                           | 89                     | 321                  | 0.001   |
| HTN                          | 109                    | 315                  | 0.001   |
| IHD                          | 18                     | 58                   | 0.082   |
| CKD                          | 26                     | 20                   | 0.001   |
| BA                           | 15                     | 91                   | 0.030   |
| COPD                         | 5                      | 8                    | 0.052   |
| Carcinoma                    | 9                      | 13                   | 0.001   |
| Liver disease                | 5                      | 7                    | 0.001   |
| IBD                          | 4                      | 0.8                  | 0.070   |
| Others                       | 2                      | 2                    | 0.071   |
| Major symptoms               |                        |                      |         |
| Fever                        | 135                    | 623                  | 0.049   |
| Cough                        | 123                    | 615                  | 0.878*  |
| Body ache                    | 11                     | 137                  | 0.001   |
| Anemia                       | 4                      | 2                    | 0.045   |
| Diarrhea                     | 26                     | 161                  | 0.029   |
| SOB                          | 72                     | 304                  | 0.085   |
| Lethargy                     | 12                     | 25                   | 0.008*  |
| Chest pain                   | 6                      | 3                    | 0.213   |
| ICU Required                 | 130                    | 102                  | 0.001   |

s= significant, ns= not significant

P-value from Unpaired t-test, Chi-square test.

Discussion
The second wave of COVID-19 has had a catastrophic impact on the Indian subcontinent, resulting in much greater infection rates, ICU utilization and death compared with the first wave (Graichen, 2021, Jain, 2021). According to current data, critical care units and mechanical ventilators are only accessible at a rate of 0.1 to 2.5 per 100000 persons in low and middle-income nations like Bangladesh (Lombardi et al., 2020). Furthermore, a recent study found that critically ill patients had a longer hospital stay with a death rate of up to 60%, resulting in a scarcity of critical care resources (Sang et al., 2021). The objective of this pioneer study was to evaluate the clinico-demographic profile, ICU utilization and death rate of COVID-19 admitted patients during the second wave in our country.

The average age of participants in this research was 54.47±12.73 years, with the majority of patients (48.3%) aged 41–60. Rahim et al. (2021) and another retrospective study from Germany found a comparable average age and majority age group (Brehm et al., 2021, Rahim et al., 2020). The present study demonstrated older age and male predominance (64.1%) among COVID-19 patients. Several studies performed in the Indian subcontinent and Europe have found a similar age and gender predominance (Ali et al., 2021, Brehm et al., 2021, Rahim et al., 2020). It has been proposed that females are more resistant to infections than men and that women have a more responsible attitude toward the COVID-19 pandemic than men (Bwire, 2020, Kopel et al., 2020). On the other hand, due to unavoidable physiological changes and possibly un-
derlying comorbid conditions that occur with ageing, older people are more susceptible to infection (Divo et al., 2014). Our observations revealed that 65.7% of patients had one or more comorbidities, similar to findings reported from studies in Italy and China (Grasselli et al., 2020, Yu et al., 2020). The most frequent comorbidities in this study were HTN (43.6%) and DM (42.1%). In previous studies in Bangladesh and other countries, DM and HTN were the two most prevalent comorbidities (Mowla et al., 2020, Nelson et al., 2020, Singh et al., 2020). Fever (77.9%) and cough (75.9%), followed by shortness of breath (38.6%), diarrhea (19.1%) and body aches (15.2%), were the dominant clinical manifestations. Previous research also found that fever and cough were the most prevalent symptoms of COVID-19 patients (Di Gennaro et al., 2021, Mowla et al., 2020).

In this study, the overall mortality rate was 16.5%. Earlier statistics from the Indian subcontinent reported a somewhat lower overall mortality rate of 13.72% (Malhotra et al., 2021). Patients who died were older and had a higher percentage of DM, HTN and CKD. In their study, Oliveira et al. (2021) observed that mortality is influenced by older age, CKD and ICU admission (Oliveira et al., 2021). The average total lung involvement in chest HRCT among all hospitalized patients was 44.83±19.87, with nearly half of patients having total lung involvement of 26%-50%, indicating a larger involvement than an earlier study (Alam et al., 2020). In the present study, out of 972 patients, 232 (23.8%) required intensive care support, and the mortality rate among the ICU patients was 56.1%. Previous studies from United Kingdom and United States of America reported an ICU utilization rate of 19.6% with a case fatality rate of 35% (Armstrong et al., 2021, Karaca-Mandic et al., 2020). However, earlier research in Bangladesh reported ICU utilization of <10% (Hossain et al., 2020). The higher overall mortality and ICU mortality and increased ICU utilization with greater total lung involvement in the present study indicate that the disease variant is more severe. In their study, Pijls et al. (2021) found that being older is strongly linked with intensive care support and Ahlstrand et al. reported that CT severity score for COVID-19 patients is a strong predictor of ICU admission (Ahlstrand et al., 2021, Pijls et al., 2021).

Our study had some limitations. It was carried out at a single tertiary care COVID-19 specialized referral facility; therefore, the proportion of critically ill patients may be higher than in other centers or in population-based research. Furthermore, the case series assessed the clinical history while in the hospital without any follow-up data. Therefore, information on recurrences was not documented. Nevertheless, this was a pioneer study on the second wave in Bangladesh. Our findings will serve as a baseline for upcoming multicentered studies and comparing with past or future waves.

Conclusions

Our findings are comparable to studies performed elsewhere; nevertheless, our investigation identified higher overall mortality and ICU death rates, increased ICU utilization and larger total lung involvement during the current wave. The mortality rate of elderly patients was also higher. The most frequent symptoms were cough and fever, and the most prevalent comorbidities were DM and HTN. Age, presence of chronic renal disease, and the need for ICU care were all significant predictors of mortality. The percentage of lung involvement was also higher in those who died.

Ethical approval

The Ethical and Scientific Committee of the tertiary care COVID-19 specialized hospital approved the protocol.

Funding

This study received no particular funding from any source.

Competing interests

None

Acknowledgement

The authors are grateful for the gracious assistance of the microbiology and radiology departments at the center where the study was carried out.

References

Ahlstrand E, Cajander S, Cajander F, Ingberg E, Löf E, Wegener M, et al. Virtual scoring of chest CT at hospital admission: time and intensive care admission in Covid-19. Infectious Diseases 2021;53(8):622–32. doi:10.1053/j.jicid.2021.1910727.
Al-Mayawee AM, Hum Abdullah, Fayyadh NAH. Spectrum of CT appearance and CT severity index of COVID-19 pulmonary infection in correlation with age, sex, and PCR test: an Iraqi experience. Egyptian Journal of Radiology and Nuclear Medicine 2021;52(1). doi:10.1186/s43055-021-00422-3.
Alam SZ, Muid SMA, Akhter A, Rahman AKMS, Emran MA, Mostak MTA. HRCT Chest Evaluation of COVID-19 Patients: Experience in Combined Military Hospital Dhaka, Bangladesh. Journal of Bangladesh College of Physicians and Surgeons 2020.1–8. doi:10.5829/jbpcs.380.4741.
Ali MB, Hasan MA, Rahman MS, Bilal M, Karmakar S, Shimu AS, et al. Clinical manifestations and socio-demographic status of COVID-19 patients during the second-wave of pandemic: A Bangladesh experience. Journal of Infection and Public Health 2021. doi:10.1016/j.jiph.2021.06.011.
Armstrong KA, Kane AD, Kistmimovic E, Oglesby FC, Cook TM. Mortality in patients admitted into intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia 2021;76(4):537–48. doi:10.1111/anae.15425.
Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, et al. ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019. Crit Care Med 2020;48:9299–304. doi:10.1097/CCM.0000000000004557.
Brehm TT, Heier A, Roedl K, Jarzacek D, Nierhaus A, Nenisch MF, et al. Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. J Clin Med 2021;10(11). doi:10.3390/jcm101129274.
Bwiere GM. Coronavirus: Why are Men more Vulnerable to Covid-19 Than Women? SN Compr Clin Med 2021:1–3. doi:10.1007/s42099-020-00341-w.
Chan JSW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395(10223):514–23. doi:10.1016/S0140-6736(20)30154-9.
Cacchione D, Vanelli M. WHO Declares Coronavirus COVID-19 a pandemic. Acta Biomed 2020;91(1):157–60. doi:10.23750/abn.v91i1.9397.
Di Gennaro F, Ithimie S, López-Azcona AF, Vallverdú T, Hernández-Flax S, de Febrer G, et al. First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain. PloS One 2021;16(3). doi:10.1371/journal.pone.0246229.
Divo MJ, Martínez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014;44(4):1055–68. doi:10.1183/09031936.00059814.
Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020;30(12):6808–17. doi:10.1007/s00330-020-07033-y.
Graechen H. What is the difference between the first and the second/third wave of Covid-19? German perspective. J Orthop 2021;24:AI–3. doi:10.1016/j.jo.2021.01.011.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabras L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323(16):1574–81. doi:10.1001/jama.2020.4713.
Hossain HT, Chowdhury T, Majumder MJ, Ava AR, Rahman QAA, Md Z, et al. Demographic and Clinical profile of 190 COVID-19 Patients in a Tertiary Care Private Hospital of Dhaka, Bangladesh: An Observational Study. Journal of Medicine 2020;21(2):82–8. doi:10.3239/jcm.v21i2.2741.
Jain VK, Iyerang RP, Vaidhya R. Differences between First wave and Second wave of COVID-19 in India. Diabetes Metab Syndr 2021;15(3):1047–8. doi:10.1016/j.dsx.2021.05.009.
Karaca-Mandic P, Sen S, Georgakopoulos A, Zhu Y, Baru A. Association of COVID-19-Related Hospital Use and Overall COVID-19 Mortality in the USA. J Gen Intern Med 2020. doi:10.1007/s11606-020-06084-7.
Kopel J, Persietti A, Roghani A, Aziz M, Gajendran M, Goyal H.racial and Gender-Based Differences in COVID-19. Front Public Health 2020;8:418. doi:10.3389/fpubh.2020.00418.
Lippi G, Sanchis-Gomar F, Henry BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Annals of Translational Medicine 2020;8(7):497. doi:10.21037/antm-20-2507.
Lombardi A, Consonni D, Garugno M, Bozzi G, Mangioni D, Muscatello A, et al. Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy. Clin Microbiol Infect 2020;26(10):1413 e9. doi:10.1016/j.cmi.2020.09.012.
Malhotra V, Baru S, Sharma N, Kumar S, Garg S, Dushaynt K, et al. Outcomes among 10,314 hospitalized COVID-19 patients at a tertiary care government hospital in Delhi, India. J Med Virol 2021;93(7):4553–8. doi:10.1002/jmv.26560.
Mowla SGM, Azad KAK, Kabir A, Biswas S, Islam MR, Banik GC, et al. Clinical Profile of 100 Confirmed COVID-19 Patients Admitted in Dhaka Medical College Hospital, Dhaka, Bangladesh. Journal of Bangladesh College of Physicians and Surgeons 2020;29-36. doi:10.3329/jbcps.v38i0.47445.

Nelson LM, Simard JP, Ohuyomi A, Nava V, Rosas LG, Bondy M, et al. US Public Concerns About the COVID-19 Pandemic From Results of a Survey Given via Social Media. JAMA Intern Med 2020;180(7):1020–2. doi:10.1001/jama intern med.2020.1369.

Oliveira E, Farihah A, El-Tahan MR, Lopez-Ruiz A, Carrillo M, Goldberg J, et al. ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. Plos One 2021;16(3). doi:10.1371/journal.pone.0249038.

Pijls F, Jolani S, Afterley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open 2021;11(1). doi:10.1136/bmjopen-2020-044640.

Rahim F, Amin S, Noor M, Bahadur S, Gul H, Mahmood A, et al. Mortality of Patients With Severe COVID-19 in the Intensive Care Unit: An Observational Study From a Major COVID-19 Receiving Hospital. Cureus 2020;12(10):e10906. doi:10.7759/cureus.10906.

Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Ann Hepatol 2020;19(4):353–8. doi:10.1016/j.ajohep.2020.05.001.

Sang S, Sun R, Coquart J, Carmichael H, Seto F, Hernandez-Boussard T. Learning From Past Respiratory Infections to Predict COVID-19 Outcomes: Retrospective Study. J Med Internet Res 2021;23(2):e23026. doi:10.2196/23026.

Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive co-hort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr 2020;14(4):283-7. doi:10.1016/j.dsx.2020.03.016.

Soriano V, Granado-Pinilla F, Sanchez-Santos M, Gomez-Gallego F, Barreiro P, de Mendoza C, et al. Main differences between the first and second waves of COVID-19 in Madrid, Spain. Int J Infect Dis 2021;105:374–6. doi:10.1016/j.ijid.2021.02.115.

Taboada M, Gonzalez M, Alvarez A, Diaz M, Costa J, Alvarez J, et al. First, second and third wave of COVID-19: What have we changed in the ICU management of these patients? Journal of Infection 2021;82(6):e14–e5. doi:10.1016/j.jinf.2021.03.027.

WHO. World Health Organization. Coronavirus (COVID-19) Dashboard: Global Situation; 2021 [Internet]. [cited 11July 2021]. Available from: https://covid19.who.int/.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239–42. doi:10.1001/jama.2020.2614.

Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care 2020;24(1):219. doi:10.1186/s13054-020-02939-x.